ZFIN ID: ZDB-FISH-161027-2
Fish name: s705Tg
Genotype: s705Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by s705Tg
No data available
GENE EXPRESSION
Gene expression in s705Tg
RNA expression
Expressed Gene Structure Conditions Figures
amotl2b standard conditions Fig. 2 from Cox et al., 2016
ccn2a standard conditions Fig. 2 from Cox et al., 2016
ccn1l2 standard conditions Fig. 2 from Cox et al., 2016
glula standard conditions Fig. 2 from Cox et al., 2016
glulb standard conditions Fig. 2 from Cox et al., 2016
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab9-rps6 control Fig. 6 from Cox et al., 2016
Ab11-akt control Fig. 6 from Cox et al., 2016
Ab11-akt chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
Ab9-rps6 chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
Ab5-akt chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
Ab5-rps6 control Fig. 6 from Cox et al., 2016
Ab6-pcna control Fig. 7 from Cox et al., 2016
Ab5-akt control Fig. 6 from Cox et al., 2016
Ab5-rps6 chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
Ab6-pcna chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
Reporter gene expression No data available
PHENOTYPE
Phenotype in s705Tg
Phenotype Conditions Figures
liver ab5-akt labeling decreased amount, abnormal chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
liver ab9-rps6 labeling decreased amount, abnormal chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
liver ab5-akt labeling increased amount, abnormal chemical treatment: methionine sulfoximine Fig. 6 from Cox et al., 2016
liver ab9-rps6 labeling increased amount, abnormal chemical treatment: methionine sulfoximine Fig. 6 from Cox et al., 2016
liver glulb expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver ccn1l2 expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver amotl2b expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver ccn2a expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver glula expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver increased mass, abnormal control Fig. 7 from Cox et al., 2016
liver size, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
liver cell population proliferation increased occurrence, abnormal control Fig. 7 from Cox et al., 2016
liver cell population proliferation occurrence, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
liver glutamate-ammonia ligase activity increased occurrence, abnormal standard conditions Fig. 4Fig. 7 from Cox et al., 2016
liver glutamate-ammonia ligase activity occurrence, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
liver nucleotide biosynthetic process increased occurrence, abnormal control Fig. 7 from Cox et al., 2016
liver nucleotide biosynthetic process occurrence, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016

CITATIONS  (1)